Stay updated on Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The footer revision identifier advances from v3.7.0 to v3.7.1, while the page continues to show a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-11T21:53:22.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, replacing the previous trial details with an access-denied screen. This indicates the study record is temporarily unavailable to users.
    Difference
    21%
    Check dated 2026-09-20T19:22:00.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    Revision tag updated from v3.6.5 to v3.6.6 on the page, indicating a newer version of the ClinicalTrials.gov entry. This reflects a page refresh or minor metadata update without altering the study details.
    Difference
    0.1%
    Check dated 2026-08-30T22:31:07.000Z thumbnail image
  6. Check
    67 days ago
    Change Detected
    Summary
    The revision label on the page was updated from v3.6.4 to v3.6.5, signaling a minor patch. No visible study details or core functionality are affected.
    Difference
    0.0%
    Check dated 2026-08-09T11:06:58.000Z thumbnail image
  7. Check
    82 days ago
    Change Detected
    Summary
    The page revision label was updated from v3.6.3 to v3.6.4, indicating a software update. The underlying study information and user-facing content remain unchanged.
    Difference
    0.0%
    Check dated 2026-07-25T17:49:04.000Z thumbnail image
  8. Check
    103 days ago
    Change Detected
    Summary
    Footer text now includes Moffitt center branding and a new revision tag (v3.6.3). The old revision tag (v3.6.2) was removed.
    Difference
    0.2%
    Check dated 2026-07-04T13:13:06.000Z thumbnail image

Stay in the know with updates to Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.